Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Rheumatoid factor IgA inhibitory polypeptide and application thereof

A rheumatoid factor and peptide-inhibiting technology, applied in the direction of peptides, specific peptides, antibodies, etc.

Inactive Publication Date: 2015-11-18
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Inhibition of IgA-RF can effectively treat juvenile rheumatoid arthritis, but there is no well-developed IgA-RF inhibitory peptide available

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rheumatoid factor IgA inhibitory polypeptide and application thereof
  • Rheumatoid factor IgA inhibitory polypeptide and application thereof
  • Rheumatoid factor IgA inhibitory polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Immunoprotective effect of rheumatoid factor IgA inhibitory polypeptide in collagen-induced mouse arthritis animal model

[0013] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of rheumatoid factor IgA inhibitory polypeptide on collagen-induced arthritis (CIA) in mice. Using mice as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPRLab.AnimalLtd), animal production license number: SCXK (Shanghai) 2008- 0016), male, 4-5 weeks old, were randomly divided into 6 groups, which were normal control group, model control group, 3 dosage groups of low, medium and high polypeptide (0.4, 0.8, 1.6mg / kg) and positive drug control group (A aminopterin 2mg / kg). Except the normal group, mice CIA models were established in each experimental group on the 0th day by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and overnight in a refrigerator at 4°C. On the da...

Embodiment 2

[0020] The immune protection effect of rheumatoid factor IgA inhibitory polypeptide on adjuvanted rat arthritis animal model in vivo

[0021] An animal model of adjuvant arthritis in rats was constructed to study the therapeutic effect of the polypeptide on Adjuvantarthritis (AA) rats. Rats were used as experimental animals, SPF grade SD rats (provided by Shanghai SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008-0016), male , with a body weight of 100g-120g, were randomly divided into 6 groups, which were normal control group, model control group, 3 dosage groups (0.2, 0.4, 0.8mg / kg) and positive drug control group ( Methotrexate 1mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10mg / ml) in the left rear of the rat. 0.1ml caused rat adjuvant arthritis model. Subcutaneous injection administra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, and in particular to a polypeptide which has an effect of inhibiting a rheumatoid factor IgA, and can be used for preventing and treating juvenile rheumatoid arthritis. The sequence of the polypeptide is EFVFLLKGHEDLRQDERVMQ which is a brand-new sequence. The polypeptide provided by the invention has the beneficial effects that the polypeptide can be used for treating the juvenile rheumatoid arthritis and has a potential new medicine development value.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a polypeptide for treating or preventing juvenile rheumatoid arthritis. Background technique: [0002] Juvenile rheumatoid arthritis (JRA) is a common connective tissue disease in childhood, characterized by chronic arthritis and multi-system involvement, including joints, skin, muscles, liver, spleen, etc. , lymph nodes. Younger children often have persistent irregular fever first, and their systemic symptoms are more significant than joint symptoms. [0003] For the treatment of children with rheumatoid arthritis, in addition to symptomatic treatment with non-steroidal anti-inflammatory drugs, slow-acting drugs should be started as soon as possible. Immunosuppressants are highly toxic and should only be used with caution in severe cases. For patients with mild symptoms, choose non-steroidal anti-inflammatory drugs suitable for children such as aspirin. Because children are more pro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/42A61K39/395A61P29/00A61P19/02
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com